UniProtKB/Swiss-Prot Q5T1R4 : Variant p.Ala2023Pro
Transcription factor HIVEP3
Gene: HIVEP3
Feedback ?
Variant information
Variant position:
2023
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LB/B
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Alanine (A) to Proline (P) at position 2023 (A2023P, p.Ala2023Pro).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from small size and hydrophobic (A) to medium size and hydrophobic (P)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
-1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
2023
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
2406
The length of the canonical sequence.
Location on the sequence:
PQASAPSPPGLHVDPGRGMG
A LPCGSPRLQLSPLTLCPLGR
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human PQASAPSPPGLHVDPGRGMGA LPCGSPRLQLSPLTLCPLGR
Mouse AQASVTSTPGPQMGPGRDLGP HLCGSPRLELSCLTPYPIGR
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 2406
Transcription factor HIVEP3
Region
1818 – 2033
Disordered
Literature citations
Structure of the human zinc finger protein HIVEP3: molecular cloning, expression, exon-intron structure, and comparison with paralogous genes HIVEP1 and HIVEP2.
Hicar M.D.; Liu Y.; Allen C.E.; Wu L.-C.;
Genomics 71:89-100(2001)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1); FUNCTION; ALTERNATIVE SPLICING; DOMAIN; VARIANTS ARG-575; PRO-2023; ALA-2109; ARG-2272 AND ALA-2339;
Prediction of the coding sequences of unidentified human genes. XVIII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro.
Nagase T.; Kikuno R.; Nakayama M.; Hirosawa M.; Ohara O.;
DNA Res. 7:273-281(2000)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2); VARIANTS ARG-575; PRO-2023; ALA-2109 AND ALA-2339;
The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2); VARIANTS ARG-575; PRO-2023; ALA-2109 AND ALA-2339;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.